These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 23583268)

  • 1. Targeting ATR in DNA damage response and cancer therapeutics.
    Fokas E; Prevo R; Hammond EM; Brunner TB; McKenna WG; Muschel RJ
    Cancer Treat Rev; 2014 Feb; 40(1):109-17. PubMed ID: 23583268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Pathways: Targeting ATR in Cancer Therapy.
    Karnitz LM; Zou L
    Clin Cancer Res; 2015 Nov; 21(21):4780-5. PubMed ID: 26362996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical strategies for development of ATR inhibitors.
    Llona-Minguez S; Höglund A; Jacques SA; Koolmeister T; Helleday T
    Expert Rev Mol Med; 2014 May; 16():e10. PubMed ID: 24810715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
    Myers K; Gagou ME; Zuazua-Villar P; Rodriguez R; Meuth M
    PLoS Genet; 2009 Jan; 5(1):e1000324. PubMed ID: 19119425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
    Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
    Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    Gralewska P; Gajek A; Marczak A; Rogalska A
    J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
    Ngoi NY; Sundararajan V; Tan DS
    Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
    Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade.
    Ngoi NYL; Peng G; Yap TA
    Annu Rev Med; 2022 Jan; 73():231-250. PubMed ID: 34644155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
    Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
    J Virol; 2019 May; 93(9):. PubMed ID: 30787154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis.
    Biswas H; Makinwa Y; Zou Y
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity.
    Patel A; Seraia E; Ebner D; Ryan AJ
    Int J Cancer; 2020 Sep; 147(5):1474-1484. PubMed ID: 32159854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
    Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
    Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New horizons in lung cancer management through ATR/CHK1 pathway modulation.
    Thapa R; Afzal O; Bhat AA; Goyal A; Alfawaz Altamimi AS; Almalki WH; Alzarea SI; Kazmi I; Singh SK; Dua K; Thangavelu L; Gupta G
    Future Med Chem; 2023 Oct; 15(19):1807-1818. PubMed ID: 37877252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the replication stress response in cancer.
    Forment JV; O'Connor MJ
    Pharmacol Ther; 2018 Aug; 188():155-167. PubMed ID: 29580942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA-PKcs is required to maintain stability of Chk1 and Claspin for optimal replication stress response.
    Lin YF; Shih HY; Shang Z; Matsunaga S; Chen BP
    Nucleic Acids Res; 2014 Apr; 42(7):4463-73. PubMed ID: 24500207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.